Dr. Rockx received his PhD from Utrecht University in 2004 for studies
on Norovirus susceptibility and antibody responses. Following his PhD,
Barry moved to the USA where he initially worked on the evolution and
pathogenesis of SARS-CoV and the development of broadly reactive
therapeutic antibodies as a post-doctoral fellow at the University of
North Carolina. He subsequently joined the Laboratory of Virology at the
Rocky Mountain Laboratories of the National Institutes of Health in
Montana where he studied the pathogenesis and vaccine development of
SARS-CoV, influenza, henipaviruses and filoviruses. He continued this
line of research as a tenure-track Assistant Professor at the University
of Texas Medical Branch. In 2014, Barry returned to The Netherlands as
Head of the Department of Rare and Emerging Viral Infections and
Response at the Center for Infectious Disease Control of the National
Institute for Public Health and the Environment in Bilthoven. Since
2016, Barry is Head of the Exotic Viruses Workgroup in the Department of Viroscience at Erasmus MC.
main research involves studies on the tropism, pathogenesis and
host responses of emerging zoonotic viruses causing hemorrhagic,
respiratory and neurological diseases, including orthohantaviruses and
arboviruses in a variety of in vitro and in vivo models at. He has
authored over 50 peer-reviewed scientific publications, several book
chapters and has supervised several post-doctoral fellows and students.
He has coordinated several NIH funded projects and contracts, and is
currently Taskleader in EU Horizon 2020 and ZonMw funded projects.
Search PubMed for Dr. Rockx' publications.